<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646815</url>
  </required_header>
  <id_info>
    <org_study_id>LM2008</org_study_id>
    <nct_id>NCT00646815</nct_id>
  </id_info>
  <brief_title>Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency</brief_title>
  <official_title>Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further characterize the treatment related changes in insulin
      sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in patients with
      growth hormone deficiency (GHD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>before and after 3 months treatment with growth hormone</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>substrate metabolism</measure>
    <time_frame>before and after 3 months of growth hormone treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intrahepatic lipid content</measure>
    <time_frame>before and after 3 months of growth hormone treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intramyocellular lipid content</measure>
    <time_frame>before and after 3 months of growth hormone treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>growth hormone (genotropin)</intervention_name>
    <description>Dosage regulation will follow the local recommendations of GHD treatment</description>
    <arm_group_label>a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Must be of legal age and competent

          -  Age: &gt;18 and &lt;60 years old

          -  Presently diagnosed with growth hormone deficiency; if panhypopituitary, the patient
             must be sufficiently substituted in the other axis´s, for at least 3 months before
             inclusion in the study

        Exclusion Criteria:

          -  Alcohol consumption &gt;21 units per week

          -  Malignant disease

          -  Pregnancy

          -  Magnetic implants or material in the body

          -  Claustrophobia

          -  BMI &gt;30

          -  Heart disease (NYHA &gt;2)

          -  Uncontrolled hypertension

          -  Manifest diabetes mellitus

          -  Change in medication, with any influence on glucose metabolism, 2 months prior to and
             until the end of the trial.

        Controls are matched on age, gender and BMI

        Inclusion Criteria:

          -  Written informed consent

          -  Must be of legal age and competent

        Exclusion Criteria:

          -  Alcohol consumption &gt;21 units per week

          -  Malignant disease

          -  Pregnancy

          -  Magnetic implants or material in the body

          -  Claustrophobia

          -  Heart disease (NYHA &gt;2)

          -  Uncontrolled hypertension

          -  Manifest diabetes mellitus

          -  Change in medication, with any influence on glucose metabolism, 2 months prior to and
             until the end of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens OL Jorgensen, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Department M, Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Sygehus, Denmark.</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department M, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://cvk.sum.dk/CVK/Home/English.aspx</url>
    <description>Central Denmark Region Committee on Biomedical Research Ethics</description>
  </link>
  <link>
    <url>http://person.au.dk/da/joj@afdm.au.dk/act</url>
    <description>Jens Otto Lunde Jorgensen</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>October 21, 2009</last_update_submitted>
  <last_update_submitted_qc>October 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Louise Møller</name_title>
    <organization>Medical department M (Endocrinology and Diabetes), Aarhus University Hospital, Aarhus Sygehus, Denmark</organization>
  </responsible_party>
  <keyword>insulin sensitivity</keyword>
  <keyword>substrate metabolism</keyword>
  <keyword>fatty liver</keyword>
  <keyword>intramyocellular lipids</keyword>
  <keyword>growth hormone deficiency</keyword>
  <keyword>Growth hormone deficiency (Adult)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

